viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies unveils new therapy approach in bid to tackle coronavirus

Last month, the Canadian firm said it was joining the fight against the deadly coronavirus

ImmunoPrecise Antibodies Ltd -
IPA announced the use of PolyTope mAb Therapy, which it says is enabled by its diverse discovery platforms and AI capabilities

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA), the antibody discovery specialist, on Thursday outlined a new approach to develop innovative treatments to fight the killer coronavirus -  now declared a global pandemic. 

As revealed in late February, ImmunoPrecise is aiming to address both prophylactic and therapeutic measures to fight the virus and its associated disease, COVID-19.

Today, it unveiled the use of PolyTope mAb Therapy, which it says is enabled by Immunoprecise's diverse discovery platforms and artificial intelligence (AI) capabilities with partner EVQLV Inc.

READ: ImmunoPrecise Antibodies joins global fight against coronavirus

Last month, Immunoprecise named Dr Ilse Roodink, the firm's chair its subsidiary Talem Therapeutic's scientific committee, as its Coronavirus global project leader.

ImmunoPrecise highlighted in a statement that current vaccine strategies under development for SARS-CoV-2 are being designed to protect uninfected individuals, however, this did not address patients with 'active' diseases.

"Antibody therapies represent a potentially powerful treatment option for COVID-19 patients, however, the current, proposed curative options (including polyclonal, sensitized serum or individual monoclonal antibody therapies) are potentially susceptible to escape by viral mutation and are likely not broadly effective against multiple strains, leaving segments of the population untreatable," it said.

"Given the continuous increase in information on SARS-CoV-2 transmission, and seemingly higher than predicted mutation rates, we believe that traditional treatments and diagnostics targeting limited epitopes may present a significant liability for long-term efficacy of a therapeutic, vaccine or diagnostic," said ImmunoPrecise's chief executive and president Dr Jennifer Bath.

Roodink told investors: "Our PolyTope mAb Therapy perfectly combines the benefits of using well-defined and fully characterized monoclonal antibodies with the essential need for a multi-targeting strategy to tackle this quickly emerging virus, thereby significantly accelerating effective clinical application."

Yesterday, the World Health Organization (WHO) labelled the outbreak of the disease as a pandemic. There are 124,519 cases globally and 4,607 deaths.

Shares eased 1.37%  to C$0.72 in Toronto.

Contact the author at giles@proactiveinvestors.com

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 17.15 CAD

Market: TSX-V
Market Cap: $320.15 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...


ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

on 09/30/2020

2 min read